Impact of COVID-19 on Mohs micrographic surgery: UK-wide survey and recommendations for practice.

The coronavirus disease 2019 (COVID‐19) pandemic has overwhelmed and disrupted healthcare systems including dermatology services, worldwide. National directives were issued in the UK to reduce patient footfall within hospitals in anticipation of a deluge of COVID‐19 admissions. We conducted a survey focusing on the impact of the pandemic upon Mohs micrographic surgery (MMS) practices, and invited all British Society for Dermatological Surgery (BSDS) members undertaking MMS to complete the survey over a period of 3 weeks, commencing 27 April 2020. Our findings are relevant for the restoration of MMS services and in preparation for a ‘second spike’ of COVID‐19 cases or future pandemics.

We received 47 responses giving an estimated 52% response rate, based on the estimate of 90 MMS surgeons in the UK (we appreciate that there may be duplication if > 1 member from the same department answered the survey; however, practices can vary even between clinicians within a department).

In the majority of departments (77%), doctors and nurses were redeployed to intensive care and medical wards. As a direct consequence, 49% reported that MMS services had ceased, while 36% and 15% reported reduced and normal services, respectively. Free‐text responses questioned whether the respondent felt that the level of redeployment was necessary or excessive (and if it had come at a cost to cancer services). Clinicians also highlighted that MMS was suspended due to lack of personal protective equipment (PPE). There was confusion regarding PPE for aerosol‐generating procedures and concerns that the virus may persist in fresh frozen tissue (a risk for laboratory staff). The vast majority (96%) of respondents continuing with MMS had rationalized patients by considering high‐risk tumours, comorbidities, age and patient choice.

Where post‐MMS reconstruction was performed in‐house, 35% of respondents reported a decrease in the proportion of grafts/flaps (Fig. 1), 74% reported a decrease in the proportion of external reconstructions carried out by other specialties and 81% reported increased use of dissolvable sutures, reflecting the intention of departments to reduce additional visits for suture removal. Regarding postoperative care, 71% saw no change in prescribing prophylactic antibiotics, and 29% reported an increase.

Figure 1

Survey responses on impact of COVID‐19 on Mohs micrographic surgery (per proportion of respondents).

A large proportion (40%) of respondents reported they were not reviewing patients for MMS surgery consultations or follow‐up appointments, and of those who were reviewing, 79% were seeing fewer patients. Unsurprisingly, 91% reported a decrease in face‐to‐face consultations, while 86% and 50% reported an increase in telephone and video consultations, respectively.

Several organizations, have published guidance on treating nonmelanoma skin cancers during the pandemic but there is a paucity of guidance on MMS. The guidance pertaining to the reintroduction of elective surgical cases during the current pandemic is changing on an almost daily basis, and individual Hospital Trusts have all developed local guidelines. Thus, while position statements from national bodies such as the British Association of Dermatologists and the BSDS are desirable (70% of survey participants felt a unified decision would be helpful), it is difficult for such guidance to be too prescriptive in nature, given the rapidly evolving situation. However, deferring treatment will lead to tumour progression and increased tumour burden, resulting in more challenging reconstructions and an increased likelihood of metastasis. We propose a number of recommendations (Table 1) to minimize risks of COVID‐19 and deliver MMS services safely.

Table 1

Recommendations for Mohs micrographic surgery during the COVID‐19 pandemic.

Rationalize patients for MMS	Treat patients with high‐risk squamous cell carcinomas and other rarer tumours with metastatic potential
	Treat patients for high‐risk basal cell carcinomas if < 70 years of age without significant COVID‐19 risk factors
	Consider risk of COVID‐19 to patient household members who are in a high‐risk group
	Involve patients with informed decision‐making
	Use multidisciplinary team approach to manage complex cases
Reduce infection risk	Advise patients to self‐isolate for 1 week prior to MMS
	When patients enter department, screen them for COVID‐19 symptoms with questionnaire, check their temperature and provide them with face masks
	Restrict accompanying visitors from entering the department
	Advise patients to sit at least 2 m apart in the waiting room
	Encourage patients to wash their hands and/or use sanitizers
	Remove potential sources of infection (e.g. books, magazines) from waiting room
MMS assessment clinics	When interacting with patients outside of theatre, use surgical mask, gloves, protective apron and visor
Surgery	Replace face‐to‐face appointments with video and telephone (with photographs) consultations to reduce hospital visits
	Use dissolvable sutures to reduce inessential hospital visits
	Use FFP3 facial mask, surgical scrub suit, surgical cap, visor, gloves and a full gown
Wound care	Facilitate patients at high‐risk from COVID‐19 to wait in MMS theatre in between layers being taken and reconstruction, rather than in the waiting room
	Create a remote‐access clinic for postoperative patients to email photographs for monitoring and/or advice

To our knowledge, this is the first nationwide survey demonstrating the impact of COVID‐19 on MMS services, and it highlights significant levels of redeployment and cessation of MMS services. Although it is encouraging that departments have taken measures to reduce the number of face‐to‐face patient encounters and have rationalized patients for MMS, uncertainty remains about best practice. Multispeciality national guidance during this and future pandemics will help the safe and effective provision of MMS for patients.